企業プロフィール
Citius Pharma 株価・ニュース・カタリスト
- ティッカー:
- CTXR
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
0.54 USD (+1.73%)
終値
最終更新: 2026年10月1日
16.6M USD
時価総額
株価変動の要因
2026年10月1日 時点で CTXR は 1.73% 上昇し、$0.5402 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Critical-Care and Oncology Portfolio
Citius Pharmaceuticals develops and commercializes products for oncology, infectious disease, and other critical-care settings. The business includes a majority interest in publicly traded Citius Oncology together with wholly owned late-stage programs.
LYMPHIR in Cutaneous T-Cell Lymphoma
LYMPHIR is an FDA-approved targeted fusion protein for adults with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. Commercialization is conducted through Citius Oncology, giving the broader group an approved oncology franchise.
Mino-Lok Catheter Salvage Therapy
Mino-Lok is an antibiotic lock solution designed to treat catheter-related bloodstream infections while preserving the indwelling central venous catheter. The product combines antimicrobial and anti-biofilm components and completed a Phase 3 study that met its primary and secondary endpoints.
Halo-Lido for Hemorrhoids
Halo-Lido is a topical formulation combining halobetasol and lidocaine for symptomatic treatment of hemorrhoids. The candidate has completed a Phase 2b study, and the company is evaluating the regulatory path for further development.
Lifecycle and Combination Development
Investigator-sponsored studies are exploring LYMPHIR in sequences or combinations with other cancer treatments, including checkpoint inhibitors and CAR-T therapy. These programs may extend the clinical role of the approved product beyond its initial label.
Portfolio-Based Structure
Citius uses separate subsidiaries and strategic transactions to finance and commercialize individual assets. This structure allows the company to retain economic exposure to LYMPHIR while independently advancing Mino-Lok and Halo-Lido.
今後のカタリスト
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。